SLC16A1 Activates the STAT3/SLC7A11 Pathway to Mediate Ferroptosis Resistance and Tumor Progression in Head and Neck...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Head and neck squamous cell carcinoma (HNSCC) exhibits tumor advancement and ferroptosis resistance linked to solute carrier family 16 member 1 (SLC16A1).
• The precise molecular mechanisms underlying SLC16A1's role in HNSCC progression and ferroptosis resistance remain largely unelucidated.
• Understanding these mechanisms is crucial for developing targeted therapeutic strategies against HNSCC.

Purpose of the Study:

• To investigate the molecular basis by which SLC16A1 contributes to HNSCC tumorigenesis and ferroptosis resistance.
• To identify downstream effectors and signaling pathways regulated by SLC16A1 in HNSCC.
• To explore the therapeutic potential of targeting the SLC16A1-mediated pathway.

Main Methods:

• RNA sequencing was performed on SLC16A1-knockdown HNSCC cells and controls.
• Functional validation, including loss- and gain-of-function experiments (in vitro and in vivo xenograft models), was conducted for candidate molecules.
• Quantitative real-time polymerase chain reaction and immunoblotting were used to validate expression changes and map the signaling pathway.

Main Results:

• Solute carrier family 7 member 11 (SLC7A11) was identified as a key downstream effector of SLC16A1, mediating tumor cell proliferation and ferroptosis resistance.
• The SLC16A1-STAT3 signaling axis was found to transcriptionally upregulate SLC7A11 expression.
• SLC16A1 activation of signal transducer and activator of transcription 3 (STAT3) drives SLC7A11 upregulation.

Conclusions:

• A novel SLC16A1-STAT3-SLC7A11 signaling axis promotes HNSCC progression by conferring resistance to ferroptosis.
• This pathway represents a potential therapeutic target for overcoming treatment resistance in HNSCC.
• Targeting this axis could offer a novel strategy for HNSCC treatment.